|
For
the quarter ending june 2022, standalone net sales (including other operating income) of Pfizer has declined 20.86% to Rs 592.90 crore compared to quarter ended june 2021. Operating profit margin has declined from 38.14% to 32.36%, leading to 32.86% decline in operating profit to Rs 191.85 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 12.92% to 14.07%. Purchase of finished goods cost rose from 22.19% to 27.14%. Employee cost increased from 12.90% to 14.38%. Other expenses rose from 12.93% to 14.50%. Other income up 47.22% to Rs 18.02 crore. PBIDT fell 29.57% to Rs 209.87 crore. Provision for interest up 61.78% to Rs 3.64 crore. PBDT fell 30.26% to Rs 206.23 crore. Provision for depreciation down 1.81% to Rs 26.51 crore. Profit before tax down 33.12% to Rs 179.72 crore. Provision for tax was expense of Rs 10.84 crore, compared to Rs 68.82 crore. Effective tax rate was 24.98% compared to 25.61%. Profit after tax fell 83.72% to Rs 32.55 crore. Promoters’ stake was 63.92% as of 30 June 2022 ,compared to 63.92% as of 30 June 2021 .
Full year results analysis
Net sales (including other operating income) of Pfizer has increased 16.64% to Rs 2,610.99 crore. Operating profit margin has jumped from 31.81% to 32.01%, leading to 17.36% rise in operating profit to Rs 835.73 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 15.05% to 13.20%. Purchase of finished goods cost rose from 20.17% to 24.84%. Employee cost decreased from 16.23% to 15.04%. Other expenses fell from 16.53% to 15.78%. Other income fell 22.77% to Rs 62.65 crore. PBIDT rose 13.25% to Rs 898.38 crore. Provision for interest fell 30.58% to Rs 10.49 crore. Loan funds declined from Rs 63.23 crore as of 31 March 2021 to Rs 39.25 crore as of 31 March 2022. Inventories rose to Rs 448.90 crore as of 31 March 2022 from Rs 435.05 crore as of 31 March 2021. Sundry debtors were higher at Rs 124.27 crore as of 31 March 2022 compared to Rs 108.77 crore as of 31 March 2021. Cash and bank balance rose to Rs 1,633.33 crore as of 31 March 2022 from Rs 1,115.10 crore as of 31 March 2021. PBDT rose 14.11% to Rs 887.89 crore. Provision for depreciation rose 5.11% to Rs 115 crore. Fixed assets increased to Rs 248.24 crore as of 31 March 2022 from Rs 224.70 crore as of 31 March 2021. Intangible assets declined from Rs 672.36 crore to Rs 622.04 crore. Profit before tax grew 15.58% to Rs 772.89 crore. Provision for tax was expense of Rs 160.33 crore, compared to Rs 171.11 crore. Effective tax rate was 20.74% compared to 25.59%. Profit after tax rose 23.10% to Rs 612.56 crore. Promoters’ stake was 63.92% as of 31 March 2022 ,compared to 63.92% as of 31 March 2021 . Cash flow from operating activities increased to Rs 667.08 crore for year ended March 2022 from Rs 427.33 crore for year ended March 2021. Cash flow used in acquiring fixed assets during the year ended March 2022 stood at Rs 15.31 crore, compared to Rs 17.70 crore during the year ended March 2021. Dividend update
Meeting of the Board of Directors is
scheduled to be held on Tuesday, September 6, 2022, to consider declaration of
Interim Dividend for the Financial Year ending March 31, 2023.
| Pfizer : Standalone Results | | Quarter ended | Year ended |
|---|
| Particulars | 202206 | 202106 | Var.(%) | 202203 | 202103 | Var.(%) |
|---|
| Net Sales (including other operating income) | 592.90 | 749.17 | -20.86 | 2,610.99 | 2,238.55 | 16.64 | | OPM (%) | 32.36 | 38.14 | -578 bps | 32.01 | 31.81 | 20 bps | | OP | 191.85 | 285.74 | -32.86 | 835.73 | 712.12 | 17.36 | | Other Inc. | 18.02 | 12.24 | 47.22 | 62.65 | 81.12 | -22.77 | | PBIDT | 209.87 | 297.98 | -29.57 | 898.38 | 793.24 | 13.25 | | Interest | 3.64 | 2.25 | 61.78 | 10.49 | 15.11 | -30.58 | | PBDT | 206.23 | 295.73 | -30.26 | 887.89 | 778.13 | 14.11 | | Depreciation | 26.51 | 27 | -1.81 | 115 | 109.41 | 5.11 | | PBT | 179.72 | 268.73 | -33.12 | 772.89 | 668.72 | 15.58 | | PBT before EO | 179.72 | 268.73 | -33.12 | 772.89 | 668.72 | 15.58 | | EO Income | -136.33 | 0 | - | 0 | 0 | - | | PBT after EO | 43.39 | 268.73 | -83.85 | 772.89 | 668.72 | 15.58 | | Taxation | 10.84 | 68.82 | -84.25 | 160.33 | 171.11 | -6.30 | | PAT | 32.55 | 199.91 | -83.72 | 612.56 | 497.61 | 23.10 | | P/(L) from discontinued operations net of tax | 0 | 0 | - | 0 | 0 | - | | Net profit after discontinued operations | 32.55 | 199.91 | -83.72 | 612.56 | 497.61 | 23.10 | | EPS (Rs)* | 29.47 | 43.70 | -32.56 | 133.90 | 108.77 | 23.10 | | | * EPS is on current equity of Rs 45.75 crore, Face value of Rs 10, Excluding extraordinary items. | | # EPS is not annualised | | bps : Basis points | | EO : Extraordinary items | | Figures in Rs crore | | Source: Capitaline Corporate Database |
|
|